Clinical Trials in Cleveland

Showing 2581-2600 of 9,497 trials

Safety of Bryostatin in Patients With MS

NCT06190912

This is a single-site, single-arm, single-dose, Phase 1 study of the safety of bryostatin in participants with multiple sclerosis (MS) receiving any disease modifying therapy (DMT).

Multiple Sclerosis

Robert Fox20 participantsStarted Jun 2024

Cleveland, Ohio, United States

COMPLETEDPhase 1< 1 mile

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT03260322

The primary purpose of this study is to evaluate the tolerability and safety profile of ASP8374 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumor malignancies. Also primary purpose is to characterize the pharmacokinetic profile of ASP8374 when administered as a single agent and in combination with pembrolizumab. Last primary purpose of this study is to determine the recommended Phase 2 dose (RP2D) of ASP8374 when administered as a single agent and in combination with pembrolizumab. The secondary purpose of this study is to evaluate the anti-tumor effect (objective response rate \[ORR\], duration of response \[DOR\], persistence of response after discontinuation, and disease control rate \[DCR\]) of ASP8374 when administered as a single agent and in combination with pembrolizumab. NTP: Neutropenia NHAE:Non-haematological AE GBS: Guillain-Barré syndrome"" IRR: Infusion-related reaction AST: Aspartate aminotransferase ALT: Alanine aminotransferase MS/MG: Myasthenia Syndrome/Myasthenia Gravis TRT: Treatment-related Toxicity TCP: Thrombocytopenia

Advanced Solid Tumors

Astellas Pharma Global Development, Inc.169 participantsStarted Sep 2017

Scottsdale, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +51 more locations

Safety of Bryostatin in Patients With MS

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Find Trials by Condition in Cleveland

Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

HiLo: Pragmatic Trial of Higher vs Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

DALY II USA/ MB-CART2019.1 for DLBCL

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

Visualization of the STN and GPi for DBS

Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans

Study of REM-422 in Patients With AML or Higher Risk MDS

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Assessment of a Non-invasive Device in the Management of Open Abdomen (AbCLO)

Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA